Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Imatinib Mesylate

FDA-approved product (capsule, oral), marketed as Gleevec, Imatinib Mesylate, Imkeldi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Imatinib Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acute lymphoblastic leukemia
  • B-cell acute lymphoblastic leukemia
  • Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Childhood acute lymphoblastic leukemia
  • Chronic myelogenous leukemia
  • Dermatofibrosarcoma protuberans
  • Gastrointestinal stromal tumor
  • Hypereosinophilic syndrome
  • Lymphoblastic lymphoma
  • Myelodysplastic/myeloproliferative disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bcr-abl tyrosine kinase inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Imatinib Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Imatinib Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

    NCT01933906 · start 2013-08-30

    Registered record
    Registry ID
    NCT01933906
    Conditions
    Chronic Phase Chronic Myeloid Leukemia
    Interventions
    P1101
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08-30
    Completion
    2018-11-14
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Phase Chronic Myeloid Leukemia
    InterventionP1101
    PhasePhase 1
    Registry statusCompleted

  • Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children

    NCT01898377 · start 2013-08

    Registered record
    Registry ID
    NCT01898377
    Conditions
    Chronic Graft-versus-host Disease
    Interventions
    Imatinib mesylate, Mycophenolate mofetil
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-08
    Completion
    2018-02-14
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Graft-versus-host Disease
    InterventionImatinib mesylate, Mycophenolate mofetil
    PhasePhase 2
    Registry statusTerminated

  • TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

    NCT01883219 · start 2013-06

    Registered record
    Registry ID
    NCT01883219
    Conditions
    Philadelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
    Interventions
    TKIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2013-06
    Completion
    2017-11
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia; Stem Cell Transplantation; Minimal Residual Disease
    InterventionTKIs
    PhasePhase 2
    Registry statusUnknown

  • A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer

    NCT01771458 · start 2012-10

    Registered record
    Registry ID
    NCT01771458
    Conditions
    Reccurent/Metastatic Solid Tumor Disease
    Interventions
    Targeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus; Targeted therapy based on molecular profiling : Vemurafenib; Targeted therapy based on molecular profiling : Sorafenib; Targeted therapy based on molecular profiling : Erlotinib; Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab; Targeted therapy based on molecular profiling : Dasatinib; Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication); Targeted therapy based on molecular profiling : Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2016-12
    Enrolment
    742

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReccurent/Metastatic Solid Tumor Disease
    InterventionTargeted therapy based on molecular profiling : Imatinib; Tumor biopsy; Standard Chemotherapy; Targeted therapy based on molecular profiling : Everolimus +7 more
    PhasePhase 2
    Registry statusCompleted

  • A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

    NCT01503502 · start 2011-08

    Registered record
    Registry ID
    NCT01503502
    Conditions
    Myelogenous Leukemia, Chronic
    Interventions
    flumatinib; imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2011-08
    Completion
    2014-12
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMyelogenous Leukemia, Chronic
    Interventionflumatinib; imatinib
    PhasePhase 2
    Registry statusUnknown

  • Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

    NCT01391611 · start 2011-07

    Registered record
    Registry ID
    NCT01391611
    Conditions
    Gastrointestinal Stromal Tumor (GIST)
    Interventions
    Pazopanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-07
    Completion
    2013-12
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor (GIST)
    InterventionPazopanib
    PhasePhase 2
    Registry statusTerminated

  • Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation

    NCT00990249 · start 2009-10

    Registered record
    Registry ID
    NCT00990249
    Conditions
    Leukemia; Lymphoma; Allogeneic Haematopoietic Stem Cell Transplantation; Acute Lymphoblastic Leukemia
    Interventions
    Busulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2016-05
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma; Allogeneic Haematopoietic Stem Cell Transplantation; Acute Lymphoblastic Leukemia
    InterventionBusulfan; Clofarabine; Thymoglobulin; Stem Cell Transplant
    PhasePhase 2
    Registry statusCompleted

  • Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

    NCT00802841 · start 2009-05

    Registered record
    Registry ID
    NCT00802841
    Conditions
    Chronic Myelogenous Leukemia
    Interventions
    nilotinib; imatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2014-07
    Enrolment
    191

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myelogenous Leukemia
    Interventionnilotinib; imatinib
    PhasePhase 3
    Registry statusCompleted

  • Imatinib Mesylate With or Without Surgery in Treating Patients With Metastatic Gastrointestinal Stromal Tumor That is Responding to Imatinib Mesylate

    NCT00956072 · start 2009-05

    Registered record
    Registry ID
    NCT00956072
    Conditions
    Gastrointestinal Stromal Tumor
    Interventions
    imatinib mesylate; therapeutic conventional surgery
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2009-05
    Completion
    Not recorded
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor
    Interventionimatinib mesylate; therapeutic conventional surgery
    PhasePhase 3
    Registry statusTerminated

  • Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia

    NCT00882206 · start 2009-04

    Registered record
    Registry ID
    NCT00882206
    Conditions
    Leukemia; Lymphoma
    Interventions
    cytarabine; decitabine; doxorubicin hydrochloride; imatinib mesylate; methotrexate; pegaspargase; prednisone; vincristine sulfate; vorinostat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2009-04
    Completion
    2013-01
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventioncytarabine; decitabine; doxorubicin hydrochloride; imatinib mesylate +5 more
    PhasePhase 2
    Registry statusTerminated

  • Imatinib Mesylate And Cyclophosphamide In Metronomic Administration: Dose Escalation Study Of Imatinib Mesylate

    NCT01046487 · start 2009-02-09

    Registered record
    Registry ID
    NCT01046487
    Conditions
    Cancer
    Interventions
    Imatinib mesylate, Cyclophosphamide (Dosing level 1 ); Imatinib mesylate, Cyclophosphamide (Dosing level 2); Imatinib mesylate, Cyclophosphamide (Dosing level 3); Blood sampling
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-02-09
    Completion
    2012-02
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCancer
    InterventionImatinib mesylate, Cyclophosphamide (Dosing level 1 ); Imatinib mesylate, Cyclophosphamide (Dosing level 2); Imatinib mesylate, Cyclophosphamide (Dosing level 3); Blood sampling
    PhasePhase 1
    Registry statusCompleted

  • Study Evaluating IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) Following Failure of at Least Imatinib and Sunitinib

    NCT00688766 · start 2008-08

    Registered record
    Registry ID
    NCT00688766
    Conditions
    Gastrointestinal Stromal Tumors
    Interventions
    retaspimycin hydrochloride (IPI-504); placebo; Best supportive care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-08
    Completion
    2009-05
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumors
    Interventionretaspimycin hydrochloride (IPI-504); placebo; Best supportive care
    PhasePhase 3
    Registry statusTerminated

  • Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

    NCT00324987 · start 2008-04

    Registered record
    Registry ID
    NCT00324987
    Conditions
    Gastrointestinal Stromal Tumor
    Interventions
    Bevacizumab; Imatinib Mesylate; Laboratory Biomarker Analysis; Pharmacological Study
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2008-04
    Completion
    2015-07
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Stromal Tumor
    InterventionBevacizumab; Imatinib Mesylate; Laboratory Biomarker Analysis; Pharmacological Study
    PhasePhase 3
    Registry statusTerminated

  • An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)

    NCT00618319 · start 2008-02

    Registered record
    Registry ID
    NCT00618319
    Conditions
    GIST
    Interventions
    BIIB021
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-04
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    InterventionBIIB021
    PhasePhase 2
    Registry statusCompleted

  • Long Term Therapy With Imatinib: Development of Late Side Effects and Compliance to Treatment

    NCT00632255 · start 2008-01

    Registered record
    Registry ID
    NCT00632255
    Conditions
    Chronic Myeloid Leukemia; Newly Diagnosed
    Interventions
    Imatinib
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-01
    Completion
    2009-05
    Enrolment
    88

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Myeloid Leukemia; Newly Diagnosed
    InterventionImatinib
    PhaseNot recorded
    Registry statusCompleted